Soluble variants of human recombinant glutaminyl cyclase. [PDF]
PLoS One, 2013 Recombinant human Glutaminyl Cyclase expressed in E. coli is produced as inclusion bodies. Lack of glycosylation is the main origin of its accumulation in insoluble aggregates. Mutation of single isolated hydrophobic amino acids into negative amino acids
Castaldo C +5 more
europepmc +7 more sources
Tetrahydroimidazo[4,5-c]pyridine-Based Inhibitors of Porphyromonas gingivalis Glutaminyl Cyclase. [PDF]
Pharmaceuticals (Basel), 2021 Periodontitis is a severe yet underestimated oral disease. Since it is linked to several systemic diseases, such as diabetes, artheriosclerosis, and even Alzheimer’s disease, growing interest in treating periodontitis has emerged recently.
Ramsbeck D +5 more
europepmc +4 more sources
Malaria parasite evades mosquito immunity by glutaminyl cyclase–mediated posttranslational protein modification [PDF]
Proceedings of the National Academy of Sciences of the United States of America, 2022 Glutaminyl cyclase (QC) modifies N-terminal glutamine or glutamic acid residues of target proteins into cyclic pyroglutamic acid (pGlu). Here, we report the biochemical and functional analysis of Plasmodium QC.
Surendra Kumar Kolli +2 more
exaly +6 more sources
Molecular characterization of tick salivary gland glutaminyl cyclase [PDF]
Insect Biochemistry and Molecular Biology, 2013 Glutaminyl cyclase (QC) catalyzes the cyclization of N-terminal glutamine residues into pyroglutamate. This post-translational modification extends the half-life of peptides and, in some cases, is essential in binding to their cognate receptor. Due to its potential role in the post-translational modification of tick neuropeptides, we report the ...
Chien-Chung Chao +2 more
exaly +5 more sources
Natural Products from Microalgae with Potential against Alzheimer’s Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors [PDF]
Marine Drugs, 2016 In recent years, many new enzymes, like glutaminyl cyclase (QC), could be associated with pathophysiological processes and represent targets for many diseases, so that enzyme-inhibiting properties of natural substances are becoming increasingly important.
Carola Griehl +2 more
exaly +4 more sources
The Bacteroidetes Q-rule and glutaminyl cyclase activity increase the stability of extracytoplasmic proteins. [PDF]
mBio, 2023 In Gram-negative didermal species of the phylum Bacteroidetes, the majority of pre(pro)proteins exported across the cell membrane via the Sec system follow the Q-rule: a glutamine residue immediately downstream of a leader peptide is exposed as the new ...
Szczęśniak K +7 more
europepmc +2 more sources
Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease. [PDF]
Front Aging Neurosci, 2023 Human glutaminyl cyclase (hQC) is drawing considerable attention and emerging as a potential druggable target for Alzheimer's disease (AD) due to its close involvement in the pathology of AD via the post-translational pyroglutamate modification of ...
Chen D +6 more
europepmc +2 more sources
Effect of a bacterial glutaminyl cyclase inhibitor on multi-species-biofilms. [PDF]
Front Oral HealthIntroductionModifying bacterial virulence could be an interesting alternative to antibiotics. The study aimed to examine the effects of an inhibitor targeting bacterial glutaminyl cyclase [which is selectively present in Porphyromonas gingivalis (Pg ...
Eick S +6 more
europepmc +2 more sources
An Overview of Glutaminyl Cyclase as a Promising Drug Target for Alzheimer's Disease. [PDF]
BiomedicinesAlzheimer’s disease (AD) has become an increasingly pressing concern for the aging population. Current AD treatments mainly focus on cognitive and neuropsychiatric symptoms—with few FDA-approved treatments targeting disease progression itself.
Madhusudhana R, Boyle E, Cen Y.
europepmc +2 more sources
A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies. [PDF]
Acta Neuropathol, 2021 AbstractParkinson’s disease (PD) is a progressive neurodegenerative disorder that is neuropathologically characterized by degeneration of dopaminergic neurons of the substantia nigra (SN) and formation of Lewy bodies and Lewy neurites composed of aggregated α-synuclein. Proteolysis of α-synuclein by matrix metalloproteinases was shown to facilitate its
Hartlage-Rübsamen M +17 more
europepmc +6 more sources